BioPharmSignal logoBioPharmSignal

Biotech News

Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen (RGEN)RepligenEarnings

Repligen Corporation (NASDAQ:RGEN), today reported financial results for its third quarter of 2026, covering the three-month period ended September 30, 2026. The Company is also providing updated financial guidance for the full year 2026.

Related news

RGENRepligen2025-10-28 11:30 EST

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

RGENRepligen2026-07-28 11:00 EST

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

AZTAAzenta Life Sciences2026-05-05 20:30 EST

Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029

ACHVAchieve Life Sciences2026-03-24 11:00 EST

Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

ACHVAchieve Life Sciences2026-08-11 12:30 EST

Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

WVEWave Life Sciences2026-02-26 12:30 EST

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

WVEWave Life Sciences2026-02-19 13:30 EST

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

TXG10x Genomics2021-02-17 21:03 EST

10x Genomics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Outlook for 2021

TXG10x Genomics2021-01-28 21:10 EST

10x Genomics to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021

KZRKezar Life Sciences2019-11-06 21:05 EST

Kezar Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update

View all latest news

Repligen

Bioprocessing Technology Supplier Repligen is a global life sciences company focused on technologies and systems used in biologic drug manufacturing. Its customers include biopharmaceutical developers and contract development and manufacturing organizations seeking greater efficiency, control, and scalability in production. Four Core...

Recent company news

RGENRepligen2026-10-30 10:00 EST

Repligen Announces $1 Billion Private Convertible Senior Notes Transaction

RGENRepligen2026-10-27 11:00 EST

Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

RGENRepligen2026-10-06 13:05 EST

Repligen Completes Acquisition of BioLife Solutions

RGENRepligen2026-08-26 11:30 EST

Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

RGENRepligen2026-07-28 11:00 EST

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Stock data

Close
168.48 USD
Market cap
6.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States